First U.S. Double-blind phase II trial of IVIg in Alzheimer’s disease – is IVIg under investigation by Baxter International as a potential anti-amyloid immunotherapy for Alzheimer. It contains a broad spectrum of antibodies and is currently indicated as a therapy for people with primary immunodeficiencies. IVIg contains antibodies that showed the beta-amyloid aggregates, which play a central role play a central role in Alzheimer’s disease, in two previous open-label trials that patients with mild to moderate Alzheimer’s cognitive improvement when treated with IVIg for six months.
Antidementia to Alzheimer’s Therapies continue to show progress in ICADResults from clinical trials of three potential Alzheimer’s therapies offer hope for new and better treatments of the disease, according to reports today at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease in Chicago.BMA Scotland on the public appeal at the development policies for the future of NHS engage common practice to Scotland. GP leaders have a new White Paper style consultation document to the debate and discussion, a to develop and deliver develop and deliver for of the Scottish Executive public health policy. We think that the document considers the first step in determining how can be proceed universally common and the service, patients need to and the public wants. – Ge Excerpts be from Consultation Paper:.